StratifiCare Unveils Promising Results of StratifiREY Radioembolization Effectiveness Prediction Test for Liver Cancer at SEA & ANZ Beckman Coulter User Group Meeting
- Anthony Chua
- 6 days ago
- 2 min read
StratifiCare is proud to announce the presentation of StratifiREY, our AI-powered blood test that predicts liver cancer patients’ response to yttrium-90 radioembolization (Y90-RE), at the recent SEA & ANZ CytoFLEX User Group Meeting hosted by Beckman Coulter Life Sciences.
Our R&D Scientist, Trinda Anne Ting, showcased our preliminary clinical results using Beckman Coulter’s DxFLEX clinical flow cytometer, demonstrating high predictive accuracy in identifying patients who will benefit from Y90-RE, an increasingly used internal radiation treatment for liver cancer.
What is Yttrium-90 Radioembolization (Y90-RE)?
Yttrium-90 radioembolization (Y90-RE) is a minimally invasive treatment for mid to advanced stage liver cancer, delivering targeted yttrium-90 (Y90) radiation directly into liver tumours via the bloodstream. When effective, it can shrink tumours, prolong survival, and enable surgical resection for previously untreatable cases. However, only a subset of patients responds to the therapy and until now, there has been no reliable way to predict who will benefit.
Enter StratifiREY: A Precision Oncology Breakthrough
StratifiREY is a first-in-class complementary diagnostic test designed to fill this gap. Using peripheral blood mononuclear cells (PBMCs) and advanced machine learning, it enables physicians to make informed treatment decisions before patients undergo costly and lengthy procedures. The test is run on Beckman Coulter's DxFLEX clinical flow cytometer, making it easy to adopt in clinical laboratories worldwide.
Key Milestones and Strategic Value
✅ Clinical validation in progress with the National Cancer Centre Singapore (NCCS).
✅ Test-bedding discussions underway with numerous hospitals across Asia.
✅ Engagements ongoing with Key Opinion Leaders (KOLs) across Asia.
By delivering accurate, actionable insights before treatment, StratifiREY has the potential to transform liver cancer care, reduce unnecessary procedures and improve patient outcomes.
Interested in Partnering?
We are actively seeking clinical laboratories, oncology centres, and strategic partners/investors to join us in commercializing StratifiREY in Asia and beyond. If you are exploring innovations in nuclear medicine companion/complementary diagnostics or precision medicine, we would love to connect.
📩 Contact us today to learn how StratifiREY can bring value to your loved one, healthcare organization or investment portfolio.
Commentaires